<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene T19R;T95I;E156_R158delinsG;L452R;E484Q;D614G literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.T19R;T95I;E156_R158delinsG;L452R;E484Q;D614G</span> literature reference collection</h1>
<div class="effect_section"><h2 id="syncytium_formation">Syncytium formation</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> # Using ACE2-GFP+Spike-RFP fluorescence assay, this lineage defining mutation combination from B.1.617.3 increased syncytium formation ~2.3x.<br/> (<a href="https://doi.org/10.1101/2021.10.04.463028" class="lit_link">Mishra et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="transmissibility">Transmissibility</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using a pseudovirus assay, this lineage defining mutation combination from B.1.617.3 conferred a ~4.5x infectivity advantage to the spike particles.<br/> (<a href="https://doi.org/10.1101/2021.10.04.463028" class="lit_link">Mishra et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this lineage defining mutation combination from B.1.617.3 conferred a ~11.8x drop in neutralization (NT50) [suggesting role for T19R and T95I in half the sera].<br/> (<a href="https://doi.org/10.1101/2021.10.04.463028" class="lit_link">Mishra et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
